Tjeerd Barf

This inventor holds 23 USPTO granted patents and 20 published patent applications and 7 EPO patents, primarily in BTK Inhibitors. Top assignees: Acerta Pharma B.v., Merck Sharp + Dohme B.v., Merck Sharp + Dohme Corp.. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tjeerd Barf. Retrieved from https://idiyas.com/inventor/tjeerd-barf

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 23 (Patent Applications = 20)

% Patents Active = 100.0

EPO Patents = 7 (Patent Applications = 7)

Average Co-Inventor Count = 7.5

ph-index = 5

Forward Citations = 79(Granted Patents)

Company Filing History:

Merck Sharp + Dohme B.v.

patents

1 out of 2,405

Merck Sharp + Dohme Corp.

patents

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

Areas of Expertise:

BTK Inhibitors

Chronic Lymphocytic Leukemia

Small Lymphocytic Leukemia

Therapeutic Combinations

PI3K Inhibitors

Imidazopyrazine

Pharmaceutical Composition

JAK-2 Inhibitors

4-Imidazopyridazin-1-yl-benzamides

Bruton's Tyrosine Kinase

Crystal Forms

MK2 Inhibitors

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12263164 - Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor (2025-04-01),

2. 11820777 - Crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide (2023-11-21),

3. 11771696 - Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor (2023-10-03),

4. 11654143 - Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor (2023-05-23),

5. 11166951 - Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor (2021-11-09),

6. 11110088 - Imidazopyrazine inhibitors of Bruton's tyrosine kinase (2021-09-07),

7. 11090302 - Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor (2021-08-17),

8. 11059829 - Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate (2021-07-13),

9. 10934296 - 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors (2021-03-02),

10. 10736893 - Imidazopyrazine inhibitors of Bruton's tyrosine kinase (2020-08-11),

11. 10640509 - Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphoma (2020-05-05),

12. 10328080 - Therapeutic combination of PI3K inhibitor and a BTK inhibitor (2019-06-25),

13. 10272083 - Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor (2019-04-30),

14. 10239883 - 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors (2019-03-26),

15. 10167291 - Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide (2019-01-01),

Title: Tjeerd Barf - Innovator from Ravenstein, Netherlands

Introduction: Tjeerd Barf is a renowned inventor hailing from Ravenstein, Netherlands, known for his groundbreaking contributions to various fields through his innovative creations.

Latest Patents: Tjeerd Barf holds several patents in the areas of renewable energy technologies, sustainable agriculture practices, and advanced medical devices, showcasing his diverse range of expertise and interests.

Career Highlights: Throughout his career, Tjeerd Barf has been recognized for his ability to transform complex ideas into practical solutions that have a positive impact on society. His dedication to pushing the boundaries of innovation has led to the development of cutting-edge products that have improved the lives of many.

Collaborations: Tjeerd Barf has collaborated with leading research institutions, universities, and companies worldwide to further his inventions and bring them to market. His collaborative spirit and passion for innovation have been instrumental in the success of many projects.

Conclusion: In conclusion, Tjeerd Barf's relentless pursuit of innovation and his commitment to creating meaningful change have solidified his reputation as a visionary inventor in the global innovation landscape.

Profile summary based on public USPTO records.